Overcoming acquired resistance to third-generation EGFR inhibitors by targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition, Bax activation, or both
- 31 January 2022
- journal article
- research article
- Published by Springer Nature in Oncogene
- Vol. 41 (12) , 1691-1700
Abstract
Treatment of EGFR-mutant non-small cell lung cancer (NSCLC) with mutation-selective third-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs) such as osimertinib has achieved remarkable success in the clinic. However, the immediate challenge is the emergence of acquired resistance, limiting the long-term remission of patients. This study suggests a novel strategy to overcome acquired resistance to osimertinib and other third-generation EGFR-TKIs through directly targeting the intrinsic apoptotic pathway. We found that osimertinib, when combined with Mcl-1 inhibition or Bax activation, synergistically decreased the survival of different osimertinib-resistant cell lines, enhanced the induction of intrinsic apoptosis, and inhibited the growth of osimertinib-resistant tumor in vivo. Interestingly, the triple-combination of osimertinib with Mcl-1 inhibition and Bax activation exhibited the most potent activity in decreasing the survival and inducing apoptosis of osimertinib-resistant cells and in suppressing the growth of osimertinib-resistant tumors. These effects were associated with increased activation of the intrinsic apoptotic pathway evidenced by augmented mitochondrial cytochrome C and Smac release. Hence, this study convincingly demonstrates a novel strategy for overcoming acquired resistance to osimertinib and other 3rd generation EGFR-TKIs by targeting activation of the intrinsic apoptotic pathway through Mcl-1 inhibition, Bax activation or both, warranting further clinical validation of this strategy.Keywords
Funding Information
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA217691)
This publication has 28 references indexed in Scilit:
- Small-molecule Bax agonists for cancer therapyNature Communications, 2014
- Apoptosis pathways and their therapeutic exploitation in pancreatic cancerJournal of Cellular and Molecular Medicine, 2009
- Apoptosis and cancer: the genesis of a research fieldNature Reviews Cancer, 2009
- Targeted Induction of Apoptosis in Cancer Management: The Emerging Role of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor Activating AgentsJournal of Clinical Oncology, 2005
- Promoting apoptosis as a strategy for cancer drug discoveryNature Reviews Cancer, 2005
- Apoptosis as a Novel Target for Cancer ChemopreventionJNCI: Journal of the National Cancer Institute, 2004
- Smac induces cytochrome c release and apoptosis independently from Bax/Bcl-xL in a strictly caspase-3-dependent manner in human carcinoma cellsOncogene, 2004
- Apoptosis in cancer—implications for therapySeminars in Oncology, 2004
- How cells die: Apoptosis pathways☆☆☆Journal of Allergy and Clinical Immunology, 2001
- Apoptosis modulators as cancer therapeutics.2001